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Interferon- (IFN-) is a pleiotropic cytokine produced by T cells and natural killer cells that has been implicated as a deleterious factor
in the immune-mediated demyelinating disorder multiple sclerosis. In vitro, purified developing and mature oligodendrocytes have been
shown to die in the presence of IFN- by apoptosis and necrosis, respectively. Moreover, transgenic expression of IFN- in the CNS of
mice during development results in tremor, hypomyelination, and oligodendrocyte cell loss, and IFN- expression in adult animals after
demyelinating insults inhibits remyelination. To examine the molecular mechanisms of IFN--induced oligodendrocyte injury, we
generated a transgenic mouse line [PLP/SOCS1 (proteolipid protein/suppressor of cytokine signaling 1)] that exhibits diminished oligo-
dendrocyte responsiveness to IFN- attributable to the targeted expression of SOCS1 in these cells. We demonstrate that oligodendro-
cytes in the PLP/SOCS1 transgenic mice are protected against the injurious effect of IFN-. Our data indicate that IFN- exerts a direct
deleterious effect on developing oligodendrocytes. The capacity of SOCS1 to inhibit the effects of IFN- suggests a therapeutic approach
toward protection of myelinating oligodendrocytes against the harmful effects of inflammation.
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Introduction
Interferon- (IFN-) is a pleiotropic cytokine produced by T
cells and natural killer cells that is involved in a number of im-
mune processes (Billiau, 1996). IFN- is critical to the immuno-
regulation of autoimmune demyelinating disorders of the CNS
(Panitch et al., 1987; Glabinski et al., 1999; Tran et al., 2000;
Skurkovich et al., 2001; Steinman, 2001). In addition, IFN- pro-
vides an intricate link between inflammation and oligodendro-
cyte injury. During stimulation with IFN-, oligodendrocytes
upregulate the expression of major histocompatibility (MHC)
class I molecules, as well as other surface ligands and receptors
(e.g., Fas, heat shock protein-70, and tumor necrosis factor-
receptor) that are believed to facilitate cell-mediated cytotoxicity
(Agresti et al., 1998; Pouly et al., 2000; Traugott, 2001).
IFN- has the capacity to adversely affect oligodendrocytes
and the process of myelination. In vitro, developing oligodendro-
cytes die by apoptosis, and mature oligodendrocytes succumb to
necrosis in the presence of IFN- (Agresti et al., 1996; Andrews et
al., 1998; Baerwald and Popko, 1998; Lin et al., 2005). Transgenic
expression of IFN- in the CNS of mice during the first few weeks
of postnatal development results in hypomyelination and oligo-
dendrocyte cell loss (Corbin et al., 1996; LaFerla et al., 2000; Lin et
al., 2005). Moreover, the induction of IFN- expression after
demyelinating insults significantly inhibits the remyelination
process (Lin et al., 2006). Oligodendrocyte injury in these models
has been related to dysregulation of protein synthesis and traf-
ficking, accumulation of unfolded proteins in the endoplasmic
reticulum (ER), and triggering of a proapoptotic stress response
(i.e., ER stress response) (Baerwald et al., 2000; Lin et al., 2005).
The molecular mechanism of IFN--mediated injury to de-
veloping oligodendrocytes, however, remains unclear. Because of
the global effects of IFN- on the CNS, either direct or indirect
(via microglia) modes of oligodendrocyte injury are possible.
Therefore, differentiating between oligodendrocyte-specific and
multicellular effects would allow for a better understanding of the
molecular mechanisms involved in IFN--mediated oligoden-
drocyte injury.
Suppressors of cytokine signaling (SOCS) are a family of pro-
teins that inhibit intracellular Janus kinase (Jak)/signal trans-
ducer and activator of transcription (Stat) signaling and effec-
tively “switch off” the signal transduction pathway (Starr et al.,
1997; Song and Shuai 1998; Stark et al., 1998; Sakamoto et al.,
2000; Levy and Darnell, 2002). SOCS proteins are key intracellu-
lar regulators of cytokine-mediated homeostasis, ensuring a con-
trolled cellular response (Yasukawa et al., 2000; Kubo et al.,
2003). SOCS1 is of particular interest because of its function as a
regulator of cellular responsiveness to IFN- (Starr et al., 1998;
Alexander et al., 1999; Bullen et al., 2001; Chong et al., 2001;
Tunley et al., 2001, 2002; Federici et al., 2002). Interestingly, the
levels of SOCS1 expression in the CNS under both normal and
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inflammatory conditions are very low and virtually undetectable
in oligodendrocytes (Polizzotto et al., 2000; Maier et al., 2002;
Wang and Campbell, 2002).
In this report, we describe a transgenic line of mice that ec-
topically expresses SOCS1 in oligodendrocytes under the tran-
scriptional control of the gene encoding the myelin protein pro-
teolipid protein (PLP). PLP/SOCS1 mice exhibit a normal
phenotype with diminished oligodendrocyte responsiveness to
IFN-. Moreover, we demonstrate that enforced expression of
SOCS1 protects oligodendrocytes against the injurious effects of
IFN- during development.
Materials and Methods
PLP/SOCS1 mouse line. The transgenic mouse line PLP/SOCS1 was gen-
erated using a construct containing a PLP expression cassette and SOCS1
cDNA (see Fig. 1 A). The PLP expression cassette (a kind gift from Dr.
Wendy Macklin, Cleveland Clinic, Cleveland, OH) has been described
previously and has been used for oligodendrocyte-specific expression of
a number of transgenes (Wight et al., 1993; Fuss et al., 2000; Doerflinger
et al., 2003; Gonzales et al., 2005). We used an SOCS1 cDNA clone
(kindly provided by Douglas Hilton, Walter and Eliza Hall Institute,
Melbourne, Victoria, Australia) (Starr et al., 1998) that contained a Flag-
epitope sequence that served as a marker for SOCS1 expression in PCR-
based or anti-Flag antibody-based detection methods (Einhauer and
Jungbauer, 2001). Briefly, the Flag-SOCS1 cDNA was excised from the
original expression vector pEF-FLAG-I/m4A2 with XbaI. The fragment
was Klenow filled and subcloned into an intermediate vector (modified
pNEB/193 vector) at the SmaI restriction site. The resulting pNEB193/
SOCS1 vector was further digested with AscI (partial digestion) and PacI
to release the Flag-SOCS1 fragment, which was subcloned into the
polylinker region of the PLP expression cassette at the same restriction
sites. The PLP/SOCS1 vector was digested with ApaI and SacII (partial
digestion) and a linear 15 kb transgene was isolated for microinjection
into fertilized (C57BL/6J  DBA/2J) oocytes. Offspring positive for the
transgene were identified by amplifying tail DNA by PCR using
transgene-specific primers. The identified founders were subsequently
bred with C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME)
establishing a transgenic line.
IFN--overexpressing mice. The transgenic mice MBP/IFN- (line 172)
and GFAP/tTA  TRE/IFN- (lines 184/110 and 184/67) that overex-
press IFN- in the CNS have been described previously (Corbin et al.,
1996; Gao et al., 2000; Lin et al., 2004, 2005). Briefly, MBP/IFN- (line
172) mice are transgenic animals in which IFN- expression is driven by
the myelin basic protein (MBP) transcriptional control region (Gao et al.,
2000). GFAP/tTA  TRE/IFN- are double-transgenic mice obtained by
mating single-transgenic GFAP/tTA (line 184) to single-transgenic TRE/
IFN- (lines 110 and 67) mice. The two TRE/IFN- mouse lines, line 110
and line 67, used in the experiments produce different amounts of IFN-
when crossed to GFAP/tTA mice (184/110 and 184/67) (Lin et al., 2004,
2005). GFAP/tTA  TRE/IFN- is a “tetracycline (tet)-off”-inducible
system in which the glial fibrillary acidic protein (GFAP) transcriptional
control region drives the expression of tetracycline-dependent transcrip-
tion activator (tTA), which in turn, binds to the TRE (tet-responsive
element) and initiates the expression of IFN-. Administration of doxy-
cycline suppresses tTA DNA binding and IFN- expression, and doxy-
cycline removal allows for temporally controlled induction of IFN-
expression (Gao et al., 1999).
Mouse breeding and examination. IFN--overexpressing mice were
crossed to the PLP/SOCS1 mice in double-transgenic (MBP/IFN- 
PLP/SOCS1) and triple-transgenic (GFAP/tTA  TRE/IFN-  PLP/
SOCS1) mating systems. MBP/IFN-  PLP/SOCS1 (172  PLP/
SOCS1) mating was performed according to a standard mating protocol.
The GFAP/tTA  TRE/IFN-  PLP/SOCS1 matings were performed in
a two-step mating process: GFAP/tTA mice (line 184) were initially
crossed to PLP/SOCS1 mice, and double-positive (184  PLP/SOCS1)
offspring were then crossed to the TRE/IFN- lines 110 and 67, sepa-
rately. This second mating step was performed according to the previ-
ously described tet-off protocol. Doxycycline at 0.05 mg/ml (Sigma, St.
Louis, MO) was added to the water of impregnated female mice until
embryonic day 14, after which the animals were switched back to normal
water, thereby allowing initiation of IFN- transcription, which peaks
during the postnatal period (Lin et al., 2005).
The litters of the mating systems (F1 generation) were examined daily
and killed at postnatal day 21. Clinical evaluation included behavioral
observation and challenged ladder walking to elicit tremor. Histological
examination included quantitation of the number and density of oligo-
dendrocytes and examination of the myelination patterns. Brain tissue
was simultaneously obtained from each animal at the time of death to
verify and measure the expression of IFN- and Flag-SOCS1 (see below).
The clinical and histological findings were subsequently stratified ac-
cording to genotype. All animal procedures were conducted in compli-
ance with the National Institutes of Health Guide for Care and Use of
Laboratory Animals and were approved by the Institutional Animal Care
and Use Committee at The University of Chicago.
PCR and genotyping. All experimental animals were genotyped using
isolated tail DNA (Biotek 2000 automatic system; Beckman Coulter, Fuller-
ton, CA). PCR (Qiagen PCR kit; Qiagen, Valencia, CA) for transgene detec-
tion was performed using the following transgene-specific screening prim-
ers: Flag-SOCS1 sense primer, 5-CCAGGACGACGATGACAAGA-3;
Flag-SOCS1 antisense primer, 5-TCAGGGGTCCCCAATAGAAG-3;
MBP/IFN- sense primer, 5-ATGAGGAAGAGCTGCAAAGC-3; MBP/
IFN- antisense primer, 5-GGTGACAGACTC CAAGCACA-3; GFAP/tTA
sense primer, 5-TCGCTTTCCTCTGAACGCTTCTCG-3; GFAP/tTA
antisense primer, 5-TCTGAACGCTGTGACTTGGAGTGTCC-3;
TRE/IFN- sense primer 5-CGAATTCGAGCTCGGTACCC-3; and
TRE/IFN- antisense primer 5-CCATCCTTTGCCATTCCTCCAG-3
(Integrated DNA Technologies, Coralville, IA).
Northern blots and quantitative PCR. Total RNA was isolated from the
examined animals with TRIzol reagent (Invitrogen, Carlsbad, CA).
Northern blots were performed by separating 20 g of total RNA in a
1.2% denaturing agarose gel. The samples were transferred to a nylon
membrane and hybridized overnight with an SOCS1 probe that had been
randomly labeled by PCR (GenAmp2400; NEN/PerkinElmer, Wellesley,
MA) with [- 32P]dCTP and [- 32P]dATP (NEN/PerkinElmer). Kodak
film (Eastman Kodak, Rochester, NY) was exposed to the hybridized
membrane at 80°C for 48 h and was developed using the M7B Kodak
processor (Eastman Kodak). To evaluate the relative levels of total RNA
present in each lane the membrane was stripped and hybridized with a
radiolabeled probe specific for the 28S ribosomal RNA (Baerwald and
Popko, 1998).
Quantitative-PCR (Q-PCR) (or real-time PCR) was performed by first
reverse transcribing 1 g of DNAaseI-treated (Invitrogen) total RNA
using oligo-dT12–18 and SuperScript II reverse transcriptase (Invitrogen
RT-PCR kit). Q-PCR was performed using 20 ng of the cDNA in a
reaction containing iQSupermix and the following primers and
probes for Flag-SOCS1 and IFN-: Flag-SOCS1 sense primer, 5-
GATGACAAGACGCGCCAGATG-3; Flag-SOCS1 antisense primer, 5-
GAGGACGAGGAGGGCTCTGA-3; Flag-SOCS1 probe, 5-56FAM-
CGCACCCAGCTGGC AGCCGACATT-3BHQ-1/-3; IFN- sense primer,
5-GATATCTCGAGGAACTGGCAAAA-3; IFN- antisense primer, 5-
CTACAAAGAGTCTGAGGTAGAAAGAGATAAT-3; IFN- probe, 5-
FAM-TGGTGACATGAAAATCCTGCAGAGCCA-BHQ1–3; glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) sense primer, 5-
CTCAACTACATGGTCTACATGTTCCA-3; GAPDH antisense primer,
5-CCATTCTCGGCCTTGACTGT-3, and GAPDH probe, 5-5TxRd-XN/
TGACTCCACTCACGGCAAATTCAACG-3BHQ-2–3 (Integrated DNA
Technologies). The reactions were performed using a Bio-Rad (Hercules,
CA) I-cycler real-time PCR unit, under the following conditions: 1 cycle at
95°C for 3 min, 40 cycles at 95°C for 30 s and 60°C for 30 s (Bio-Rad). The
mRNA levels of Flag-SOCS1 and IFN- were normalized to the expression
levels of GAPDH based on threshold cycles (Flag-SOCS1/GAPDH and IFN-
/GAPDH ratios) (Lin et al., 2005).
Western blot and immunoprecipitation. Total lysates from brain and
spleen of several PLP/SOCS1 mice and wild-type mice were obtained by
tissue homogenization in radioimmunoprecipitation assay buffer (Santa
Cruz Biotechnology, Santa Cruz, CA). After incubation on ice for 15 min,
lysates were centrifuged at 14,000 rpm for 30 min, and the supernatants
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were collected. Protein samples (50 g) were electrophoresed on 15%
SDS-polyacrylamide gels, transferred to polyvinylidene difluoride mem-
branes (Trans-blot SD apparatus; Bio-Rad), incubated overnight with
mouse anti-Flag antibody (M2, diluted to 1:1000; Sigma), and detected
with ECL Western blot detection reagents (Amersham Biosciences, Pis-
cataway, NJ). Flag protein (Sigma), a polymer of the Flag oligopeptide,
was used as a positive control for the reaction.
Immunoprecipitation was performed with an immunoprecipitation
kit (Roche Molecular Biochemicals, Indianapolis, IN) by incubating the
protein extracts from the brain and spleen of PLP/SOCS1 and wild-type
mice with anti-Flag antibody (M2) for 4 h at 4°C, followed by overnight
incubation with protein A/C agarose at 4°C. The immune complexes
were collected by centrifugation at 14,000 rpm for 20S, and the protein
was separated from protein A/C agarose with kit-supplied reagents.
Western blot of the immunoprecipitated protein was performed as de-
scribed above.
Immunohistochemistry. Animals were anesthetized with 0.01 ml/g
2.5% Avertin (Sigma) administered intraperitoneally and perfused with
saline, followed by 2% paraformaldehyde for 10 min. Brains were re-
moved, postfixed for 1 h with 2% paraformaldehyde, cryopreserved with
30% sucrose for 48 h, prepared as frozen blocks (OCT compound;
Sakura, Torrance, CA), and sectioned at a thickness of 7 m at 20°C
(CM1800 cryostat; Leica, Nussloch, Germany). Before immunostaining,
the sections were treated with 0.1% Triton X-100 (Sigma) for 10 min and
incubated with 10% bovine serum albumin (Sigma) or goat serum
(Invitrogen) for 30 min. Indirect immunostaining was performed by
sequential incubation with primary antibodies (for 2 h at room temper-
ature or overnight at 4°C) and FITC-conjugated or cyanine 3
(Cy3)-conjugated secondary antibodies (for 30 min). All of the following
primary and secondary antibodies used in the study were commercially
available: mouse and rabbit anti-Flag antibody (dilution, 1:100; Sigma),
mouse anti-adenomatous polyposis coli protein (CC1) antibody (dilu-
tion, 1:20; Oncogene Sciences, Uniondale, NY), mouse MHC class I anti-
body (dilution, 1:100; Chemicon, Temecula, CA), mouse anti-PLP antibody
(dilution, 1:100; Chemicon), mouse and rabbit anti-SOCS1 antibody (dilu-
tion, 1:100; Santa Cruz Biotechnology), rabbit anti-Stat1 antibody (di-
lution, 1:100; Santa Cruz Biotechnology), anti-mouse or anti-rabbit
FITC-conjugated secondary antibody (dilution, 1:100; Jackson Im-
munoResearch, West Grove, PA), and anti-mouse or anti-rabbit Cy3-
congugated antibody (dilution, 1:500; Jackson ImmunoResearch).
The immunostained sections were mounted using Vectashield
mounting medium containing 4,6-diamidino-2-phenylindole
(DAPI) nuclear stain (Vector Laboratories, Burlingame, CA) and ex-
amined using a fluorescent microscope (Axoplan; Zeiss, Oberkochen,
Germany).
Oligodendrocyte cell density was assessed digitally using Axiovision
software (Zeiss), at postnatal day 21, as described previously (Lin et al.,
2005). The brains were sectioned sagittally through the corpus callosum
dividing the brain in two symmetrical halves. Ten frozen sections from
each half were prepared at 7 m thickness and numbered in the sequence
of their preparation. The brains of three animals per study group were
prepared in this manner. After the CC1 immunostaining, the corre-
sponding area of corpus callosum of each section was digitally selected,
and the corresponding total area was obtained. CC1 cell counting was
performed manually within the selected areas of each section, and the
number of CC1-positive (CC1 ) cells per square area (in square milli-
meter) was calculated. The results were presented as mean  SD of
CC1  cells/mm 2, with n  3 animals per study group.
Electron microscopy. Mice selected for electron microscopy studies
were perfused with 4% paraformaldehyde and 2.5% glutaraldehyde.
Brains were harvested, and white matter structures were sectioned using
a stereotype microscope (Wild M3C; Wild AG, Heebrugg, Switzerland).
The tissue was further postfixed in osmium tetroxide and embedded in
freshly prepared epoxy resin (Epon-812; Electron Microscope Sciences,
Fort Washington, PA) for 48 h at 60°C. The resin blocks were sectioned at
90 nm using Leica Ultracut ultramicrotome (Leica) and stained with 5%
uracyl acetate and 2.5% lead citrate. Ultrastructure of the tissue samples
was examined using the Tecnai-F30 transmission electron microscope
(FEI Company, Hillsboro, OR).
Myelination patterns of the examined animals were assessed at post-
natal day 21 by calculating the percentage of unmyelinated axons and
ratio of the axon/fiber diameters (G ratio) with NIH Image J software as
described previously (Lin at al., 2005). The brains were sectioned sagit-
tally through the corpus callosum dividing the brain in two symmetrical
halves. Approximately 2 mm 3 samples from the genu and the splenum of
both halves of corpus callosum were obtained using a Wild M3C stereo-
type microscope. The orientation of the specimen in the resin blocks
yielding axonal cross-sections (well seen myelin rings) was chosen and
established by toludine blue staining of a few sample sections. The resin
blocks with the chosen orientation were processed for electron micro-
scopic examination. Randomly selected areas were examined, and 10
representative pictures from both genu and splenum corpus callosum
were obtained at 12,000 magnification. The number of unmyelinated
axons was assessed by manual counting of axons that lacked myelin and
were encircled solely by their own plasma membrane. All unmyelinated
axons present in the representative images were counted, and their per-
centage was calculated by examining a total of 500 axons per tissue sam-
ple. The G ratio of myelinated axons was assessed by digitally selecting the
area encircled by the inner and outer surfaces of the myelin sheath, ob-
taining the axonal (inner) and the fiber (outer) diameters and dividing
their corresponding values (axonal diameter/fiber diameter ratio). The
brains of three animals per group were examined, and the G ratios of a
total of 150 nerve fibers from both genu and splenum were examined.
The results were presented as mean  SD of G ratio and percentage
unmyelinated axons, with n  3 animals per study group.
Mixed primary oligodendrocyte cultures and Stat1 translocation assay.
Mixed primary oligodendrocyte cultures were prepared as described pre-
viously (Baerwald et al., 2000). Briefly, brain tissue was harvested from 2-
to 3-d-old newborn pups of PLP/SOCS1 and C57BL/6J matings. Because
the litters contained transgenic and wild-type pups, the brain of each
animal was processed individually and cultured separately, and later the
genotype was matched. Each brain was digested separately using 0.25%
trypsin and 10 g/ml DNAaseI (Invitrogen) in DMEM for 20 min at
37°C, and cells were cultured on separate poly-D-lysine-coated 75 mm 2
flasks (Sigma). The cultures were maintained with 10% fetal bovine se-
rum/DMEM at 37°C with 5% CO2 for 12 d and then switched to a defined
medium containing 5 l/ml insulin, 50 g/ml transferrin, 30 nM sele-
nium, 10 nM biotin, 10 nM progesterone, 15 nM T3, 0.1% bovine serum
albumin, and 1% ampicillin–streptomycin (Sigma). On the fifth day of
differentiation, the cultures were treated with 100U/ml IFN- (Calbio-
chem, La Jolla, CA) for 30 min. Dual immunostaining for anti-PLP and
anti-Stat1 antibodies and DAPI nuclear staining were performed as de-
scribed above. The Stat1 nuclear translocation assay was performed in six
separate culture preparations. One hundred PLP-positive cells were
manually counted in both wild-type and PLP/SOCS1 cultures. The re-
sults were presented as mean  SD percentage cells positive for Stat1
nuclear translocation.
Statistical analysis. All data were generated from three independent
experiments. Means, SDs, and p values were calculated using the Average,
Stdev, and ANOVA functions in Microsoft (Redmond, WA) Excel. A
statistically significant difference was defined as a p value of 0.05.
Results
Characterization of the PLP/SOCS1 transgenic mouse line
The PLP/SOCS1 transgenic mice, which were generated as de-
scribed in Material and Methods, were designed to express Flag-
epitope-tagged SOCS1 in myelinating cells (Fig. 1A). These mice
exhibit no phenotypic abnormalities, breed and produce trans-
genic progeny in a Mendelian manner, and live a normal lifespan.
Histological evaluation, including electron microscopy, per-
formed at different time points up to 1 year of age revealed no
significant differences in the myelination patterns or the number,
density, or morphology of oligodendrocytes (see below) between
transgenic and wild-type littermates.
Expression of the PLP/SOCS1 transgene was characterized at
postnatal day 21 using several methods. Northern blot analysis
with an SOCS1 cDNA hybridization probe revealed a band of
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increased intensity in RNA samples from
the brains of transgenic mice relative to
control brain samples but not from other
tissues (Fig. 1B). Real-time PCR analysis
with transgene-specific primers revealed
the highest concentrations of transgene-
derived SOCS1 mRNA in brain, spinal
cord, and sciatic nerve, with significantly
lower levels in other organs, including
heart, thymus, spleen, and liver (Fig. 1C).
Transgene expression appeared to be sta-
ble up to 12 months of age (data not
shown).
Western blot analysis, using an anti-
body to the Flag tag, revealed a 19 kDa
band corresponding to the expected size of
SOCS1 in the PLP/SOCS1 brain lysates but
not in wild-type brain lysates or PLP/
SOCS1 spleen lysates (Fig. 1D). To further
confirm Flag-SOCS1 protein expression,
we performed immunoprecipitation with
the anti-Flag antibody, which again de-
tected a 19 kDa positive band in the PLP/
SOCS1 brain immunoprecipitates but not
in the wild-type brain or PLP/SOCS1
spleen immunoprecipitates (Fig. 1E).
Indirect immunostaining of wild-type
and PLP/SOCS1 brains with both anti-
SOCS1 and anti-Flag antibodies also dem-
onstrated expression of the transgene (Fig.
1F–I). We detected both anti-Flag and
anti-SOCS1 immunopositivity only in
PLP/SOCS1 brains.
To localize the expression of Flag-
SOCS1 in the CNS, we performed dual im-
munostaining of wild-type and PLP/
SOCS1 brain tissue with the anti-Flag
antibody and either anti-PLP antibody, a
marker for myelin, or anti-CC1 antibody,
a marker for the oligodendrocyte cell
body. We found a strong colocalization
between anti-PLP and anti-Flag antibod-
ies, as well as between anti-CC1 and anti-
Flag antibodies (data not shown), suggest-
ing that Flag-SOCS1 was localized to the
white matter and oligodendrocytes (Fig.
2). Noncolocalizing immunopositivity for
anti-Flag, anti-PLP, or anti-CC1 antibod-
ies was not detected.
We were also able to detect the ex-
pression of Flag-SOCS1 in primary
mixed oligodendrocyte cultures estab-
lished from transgenic animals by dual
immunostaining with anti-PLP and
anti-Flag antibodies (Fig. 3). Expression
of Flag-SOCS1 was detected only in cul-
tures from PLP/SOCS1 animals and only
in cells expressing PLP. Virtually all
PLP-positive cells were also positive for
Flag-SOCS1. The colocalization between
anti-Flag and anti-PLP immunoreactiv-
ity appeared to involve both the cell
body and cell processes (Fig. 3F ).
Figure 2. Colocalization of Flag-SOCS1 and PLP in vivo. Dual immunostaining of wild-type (A–C) and PLP/SOCS1 (D–F )
cerebellar tissue, harvested at postnatal day 21, was performed using anti-PLP/Cy3 (A, D, red) and anti-Flag/FITC (B, E, green)
antibodies and DAPI nuclear stain (C, F, blue). PLP-positive structures of the wild-type samples (A, red) demonstrated no immu-
nopositivity for anti-Flag (B), and no signal colocalization was established (C). In contrast, PLP-positive structures of PLP/SOCS1
samples (D) expressed Flag-SOCS1 (E), and strong colocalization between the anti-PLP and anti-Flag immunopositivity was
detected (F, yellow color signifies colocalization). Sagittal sections of cerebellum are shown. Scale bar, 20 m.
Figure 1. Expression of Flag-SOCS1. A, PLP/SOCS1 construct contains 2.4 kb of the PLP 5 flanking DNA, exon 1 (no ATG), intron
1 (diagonally striped boxes), Flag-SOCS1, and simian virus 40 (SV40) poly(A) signal sequence. Expression of the PLP/SOCS1
transgene was characterized at postnatal day 21 using several methods. B, Northern blot analysis demonstrated Flag-SOCS1
expression in PLP/SOCS1 brain (lane 2; T, transgenic brain) compared with wild-type brain (lane 1; W, wild-type brain). C, Q-PCR
analysis with transgene-specific primers revealed the highest concentrations of transgene-derived SOCS1 mRNA were in the
brain, spinal cord, and sciatic nerve, with significantly lower levels in other organs. D, Western blot. E, Immunoprecipitation. Both
demonstrated a single 19 kDa Flag-positive band, the expected molecular weight (MW) of SOCS1, only in the lanes loaded with
brain samples from PLP/SOCS1 mice (brain fSOCS1). Flag protein was used as a positive control for the antibody reaction; 15%
SDS-PAGE, anti-Flag (M2) antibody. Immunostaining with anti-SOCS1/FITC (F, H, green) and anti-Flag/FITC (G, I, green) antibod-
ies demonstrated positive signal only in PLP/SOCS1 (H, I, green) and not in the wild-type mouse samples (F, G). Cell nuclei were
contrastained with ethidium bromide (F–I, red). Coronal sections of thalamic fiber are shown. Scale bar, 20 m.
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Oligodendrocytes from PLP/SOCS1 mice exhibited
diminished responsiveness to IFN-
The responsiveness of PLP/SOCS1 oligodendrocytes to IFN-
was studied in primary mixed glial cultures. To determine
whether expression of transgenic SOCS1 would interfere with the
nuclear translocation of the IFN- signaling molecule Stat1, the
cell cultures were treated with 100U/ml IFN- for 30 min and
immunostained using anti-PLP and anti-Stat1 antibodies along
with the DAPI nuclear stain (Fig. 4). Examination of Stat1 sub-
cellular localization in wild-type cultures revealed strong colocal-
ization with DAPI-positive nuclei in all cells, including PLP-
positive oligodendrocytes. In contrast, subcellular localization of
Stat1 in PLP/SOCS1 cultures revealed a differential response to
IFN-. In transgenic PLP-positive oligo-
dendrocytes, Stat1 remained in the cyto-
plasm and did not colocalize with cell nu-
clei in the presence of IFN- (Fig. 4E–H).
This was in contrast to the response of the
surrounding PLP-negative cells, which,
similarly to wild-type cells, responded to
IFN- with Stat1 nuclear translocation.
Virtually all PLP-positive oligodendro-
cytes (96  3 cells) in the wild-type cul-
tures responded to IFN- stimulation with
Stat1 nuclear translocation. In contrast,
Stat1 nuclear translocation was detected
only in occasional PLP-positive oligo-
dendrocytes (6  2 cells) after IFN-
stimulation ( p  0.05).
We next characterized the responsive-
ness of PLP/SOCS1 oligodendrocytes to
IFN- in vivo using the induction of MHC
class I molecule expression as an indica-
tion of IFN- sensitivity. The capacity of
SOCS1 to inhibit IFN--mediated induc-
tion of MHC class I molecule was exam-
ined in a double-transgenic system. MBP/
IFN- (line 172) single-transgenic mice,
which express a low level of IFN- in the
CNS (Gao et al., 2000), were mated to PLP/
SOCS1 mice, and the single- and double-
transgenic progeny were examined for dif-
ferences in MHC class I molecule
expression (Fig. 5). MHC class I molecule
expression was detectable in neither con-
trol wild-type mice nor PLP/SOSC1 mice
(Fig. 5A–D). Consistent with previous re-
ports, MBP/IFN- mice exhibited upregu-
lated expression of the MHC class I mole-
cule, with diffuse protein localization
along the myelin sheath (Fig. 5E,F)
(Corbin et al., 1996). The double-
transgenic mice (MBP/IFN-  PLP/
SOCS1), however, displayed a differential
pattern of MHC class I molecule expres-
sion (Fig. 5G–J). As shown in Figure 5,
oligodendrocytes and myelin positive for
Flag-tagged SOCS1 did not express detect-
able levels of MHC class I molecule,
whereas cells negative for transgene ex-
pression, and in close proximity to the
SOCS1-positive cells, demonstrated
strong immunoreactivity (Fig. 5G–J).
Similar differential upregulation of MHC class I molecule expres-
sion was observed after the direct administration of IFN- in the
brain of PLP/SOCS1 mice (data not shown). Together, these data
indicate that oligodendrocytes from PLP/SOCS1 mice display di-
minished responsiveness to IFN-.
PLP/SOCS1 mice were protected against injurious IFN-
effects during development
Transgenic expression of IFN- in the CNS of developing mice
results in oligodendrocyte loss and hypomyelination (Corbin et
al., 1996; Lin et al., 2005). To determine whether SOCS1 expres-
sion could protect developing oligodendrocytes from the injuri-
Figure 3. Colocalization of Flag-SOCS1 and PLP in vitro. Dual immunostaining of wild-type (A–C) and PLP/SOCS1 (D–F ) mixed
primary oligodendrocyte cultures was performed using anti-PLP/FITC (A, D, green) and anti-Flag/Cy3 (B, E, red) antibodies.
PLP-positive oligodendrocytes in the wild-type culture (A) demonstrated no immunopositivity for anti-Flag (B), and no signal
colocalization was established (C). In contrast, PLP-positive oligodendrocytes (D) in the PLP/SOCS1 cultures expressed Flag-SOCS1
(E), and strong colocalization between anti-PLP and anti-Flag signals was detected (F ). Flag-SOCS1 appeared to be localized in the
cell body (large arrows) and cell processes (small arrows) of oligodendrocytes. Scale bar, 20 m.
Figure 4. Differential inhibition of Stat1 nuclear translocation. Mixed primary oligodendrocyte cultures from wild-type (A–D)
and PLP/SOCS1 (E–H ) mice were stimulated with 100 U of IFN- for 30 min, and dual immunostainings using anti-PLP/Cy3 (A, E,
red), anti-Stat1 (B, F, green), and DAPI nuclear stain (D, H, blue) were performed and the fluorescent signals digitally overlaid (C,
G, overlay between PLP/Cy3 and Stat1/FITC signals; D, H, overlay between PLP/Cy3, Stat1/FITC, and DAPI signals). In the wild-type
cultures, Stat1 was colocalized with DAPI-stained nuclei of all cells, including the PLP-positive oligodendrocytes (small arrows) (B,
D, colocalization between Stat1 and DAPI). In the PLP/SOCS1 cultures, Stat1 was colocalized with DAPI-positive nuclei of
the PLP-negative cells (small arrows) but not of the PLP-positive oligodendrocytes (large arrows) (F, H ). Stat1 in the
PLP-positive oligodendrocytes did not colocalize with DAPI-stained nuclei but remained in the cytoplasm (large arrows)
(F, H ). Scale bar, 10 m.
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ous effects of IFN-, we crossed PLP/SOCS1 mice to three trans-
genic mouse lines overexpressing IFN- in the CNS at different
levels, MBP/IFN- (line 172), GFAP/tTA  TRE/IFN- (lines
184/110), and GFAP/tTA  TRE/IFN- (lines 184/67) and the
following three mating systems were established (detailed in Ma-
terial and Methods): MBP/IFN-  PLP/SOCS1 (172  PLP/
SOCS1, a double-transgenic system) and GFAP/tTA  TRE/
IFN-  PLP/SOCS1 (184/110  PLP/SOCS1 and 184/67  PLP/
SOCS1, two triple-transgenic systems). The litter (F1 generation)
of each mating system was divided into four study groups de-
pending on their genotype: wild-type/single-transgenic controls,
mice expressing SOCS1 only, mice expressing IFN- only, and
mice expressing both IFN- and SOCS1. A total of 40 animals per
mating system (10 animals per each study group) were collected
and examined clinically and histologically at postnatal day 21.
Phenotypic comparisons of littermates were performed from
birth to postnatal day 21, and evaluation consisted of behavioral
observation and challenged ladder walking to elicit tremor. MBP/
IFN- (line 172) mice express low levels of IFN- in the CNS and
displayed no behavioral abnormalities, in accordance with find-
ings reported previously (Corbin et al., 1996). Mice from the F1
generation of the MBP/IFN-  PLP/SOCS1 (172  PLP/
SOCS1) mating system similarly displayed no behavioral abnor-
malities regardless of genotype. Double-transgenic GFAP/tTA 
TRE/IFN- (lines 184/110) and GFAP/tTA  TRE/IFN-
(lines184/67) mice display mild to moderate tremor that appears
during the second postnatal week and peaks by 21 d of age (Lin et
al., 2004, 2005). Mice from the F1 generation of the GFAP/tTA 
TRE/IFN-  PLP/SOCS1 mating systems exhibited tremor, the
incidence of which was dependent on genotype (Table 1). The
phenotypes of wild-type mice and single-transgenic control mice
[GFAP/tTA (line 184), TRE/IFN- (lines 67 and 110)] and PLP/
SOCS1 mice were clinically normal. The tremoring phenotype,
which varied in severity, was identified in almost all double-
transgenic GFAP/tTA  TRE/IFN- mice overexpressing IFN-:
80% (8 of 10) of 184/110 mice and 100% (10 of 10) of 184/67
mice. Triple-transgenic GFAP/tTA  TRE/IFN-  PLP/SOCS1
mice overexpressing both IFN- and SOCS1 appeared to be pro-
tected, because only 10% (1 of 10) of 184/110  PLP/SOCS1 mice
and 30% (3 of 10) of 184/67  PLP/SOCS1 mice developed
tremor (Table 1).
The clinically examined littermates of all three transgenic
mating systems were further evaluated for histological abnormal-
ities at postnatal day 21. Three animals per study group from each
mating system were examined histologically for oligodendrocyte
and myelin abnormalities. Brain tissue was obtained from each
animal at the time of death (before the fixating perfusion), and
total RNA was isolated. The possibility that SOCS1 expression
affected the expression of the IFN- transgene was examined in
all three transgenic mating systems using Q-PCR (Fig. 6A). IFN-
expression was detected in MBP/IFN- single-transgenic and MBP/
IFN-  PLP/SOCS1 double-transgenic littermates of the 172 
PLP/SOCS1 transgenic system in GFAP/tTA  TRE/IFN- double-
transgenic and GFAP/tTA  TRE/IFN-  PLP/SOCS1 triple-
transgenic littermates of the184/110  PLP/SOCS transgenic system
and in GFAP/tTA  TRE/IFN- double-transgenic and GFAP/
tTA  TRE/IFN- PLP/SOCS1 triple-transgenic littermates of the
184/67  PLP/SOC1 transgenic system. Two characteristics of
IFN- expression were observed. First, the three mating systems
differed in their expression levels: MBP/IFN-  PLP/SOCS1
(172  PLP/SOCS1) expressed the lowest, and GFAP/tTA  TRE/
IFN-  PLP/SOCS1 (184/67  PLP/SOC1) expressed the highest
IFN- levels. Second, the littermates of the same mating system,
expressing IFN- only or both IFN- and SOCS1, did not differ in
their expression levels. We found no detectible levels of IFN- in the
wild-type, the GFAP/tTA, and TRE/IFN- single-transgenic and the
PLP/SOCS1 littermates (Fig. 6A).
The cerebra of three animals per study group from all trans-
genic mating systems were processed for immunohistochemical
analysis with the CC1 antibody to determine oligodendrocyte
density (Figs. 6B, 7). The MBP/IFN- mice expressed the lowest
levels of IFN- in the CNS compared with GFAP/tTA  TRE/
Figure 5. Differential expression of MHC class I molecule in MBP/IFN-  PLP/SOCS1 mice. Wild-type (A, B), PLP/SOCS1 (C, D), MBP/IFN- (E, F ), and MBP/IFN-  PLP/SOCS1 (G–J ) mouse
brains, harvested at postnatal day 21, were dual immunostained with anti-MHC class I/FITC (A, C, E, G, I, green) and anti-flag/Cy3 (B, D, F, H, J, red) antibodies and DAPI nuclear stain (J, blue).
Wild-type samples were double negative (A, B). PLP/SOCS1 samples were negative for MHC class I molecule (C) and positive for Flag (D). MBP/IFN- samples were single positive for MHC class I
molecule (E) and negative for Flag (F ). Double-transgenic MBP/IFN- PLP/SOCS1 samples were double positive for MHC class I molecule (G) and Flag (H ). Higher magnification of MBP/IFN-
PLP/SOCS1 samples (outlined square in G, H ) revealed differential distribution of the immunopositivity (I, J ); MHC class I-positive cells (large arrows) were negative for Flag, whereas Flag-positive
cells (small arrows) were negative for MHC class I molecules. Sagittal sections of corpus callosum. Scale bars: A–H, 20 m; I, J, 10 m.
Table 1. Incidence of tremor among the transgenic littermates
Wild-type/controls SOCS1 IFN- IFN-  SOCS1
172  PLP/SOCS1 0% 0% 0% 0%
184/110  PLP/SOCS1 0% 0% 80% (8 of 10) 10% (1 of 10)
184/67  PLP/SOCS1 0% 0% 100% (10 of 10) 30% (3 of 10)
Littermates from three transgenic mating systems, 172  PLP/SOCS1, 184/110  PLP/SOCS1, and 184/67 
PLP/SOCS1 were stratified according to their genotype into four groups: wild-type/control mice, mice expressing
SOCS1 only, mice expressing IFN- only, and mice expressing both IFN- and SOCS1. Ten mice per group were
clinically followed during the first 3 postnatal weeks, and the incidence of tremor was recorded.
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IFN- mice and displayed no significant abnormalities in CC1-
positive cell density, in accordance with results reported previ-
ously (Gao et al., 2000). We found no statistically significant
difference in the oligodendrocyte density among mice from the
F1 generation of the MBP/IFN-  PLP/SOCS1 (172  PLP/
SOCS1) mating system. In the triple-
transgenic systems (GFAP/tTA  TRE/
IFN-  PLP/SOCS1), we found that the
oligodendrocyte density in mice from the
F1 generation differed depending on ge-
notype (Figs. 6B, 7). Wild-type mice and
the single-transgenic mice (PLP/SOCS1,
GFAP/tTA, and TRE/IFN-) had compa-
rable oligodendrocyte densities. We found
severe dose-dependent oligodendrocyte
loss in the GFAP/tTA  TRE/IFN- mice
overexpressing IFN- compared with the
wild-type and single-transgenic litter-
mates: 20% of oligodendrocytes were
lost in 184/110 mice (from 146  6 CC1
cells/mm 2 in the wild-type mice to 115  8
CC1 cells/mm 2 in the IFN- mice), and
40% were lost in 184/67 mice (from
144  5 CC1 cells/mm 2 in the wild-type
mice to 79  9 CC1 cells/mm 2 in the
IFN--overexpressing mice). In contrast,
GFAP/tTA  TRE/IFN-  PLP/SOCS1
triple-transgenic littermates that overex-
pressed both IFN- and SOCS1 lost statis-
tically significantly fewer oligodendrocytes
compared with mice overexpressing
IFN- only: 8% of oligodendrocytes
were lost in 184/110  PLP/SOCS1 mice
(from 141  6 CC1 cells/mm 2 in the
PLP/SOCS1 mice to 129  6 CC1 cells/
mm 2 in the IFN-- and SOCS1-overexpressing mice), and
15% were lost in 184/67  PLP/SOCS1 mice (from 142  5
CC1 cells/mm2 in the PLP/SOCS1 mice to 112  7 CC1 cells/
mm2 in the IFN-- and SOCS1-overexpressing mice) (Figs. 6B, 7).
Myelination patterns in the harvested cerebra were further
evaluated with electron microscopy, and the level of myelination
was assessed by calculating the G ratio and the percentage of
unmyelinating axons (Figs. 6C,D, 8). We found no statistically
significant difference in G ratios among wild-type, the single-
transgenic, and double-transgenic littermates from the MBP/
IFN-  PLP/SOCS1 (172  PLP/SOCS1) mating system. In the
triple-transgenic systems (GFAP/tTA  TRE/IFN-  PLP/
SOCS1), significant differences in G ratios were found among the
F1 generation mice, depending on genotype (Figs. 6C, 7). G ratios
among the wild-type and the GFAP/tTA, TRE/IFN-, and PLP/
SOCS1 single-transgenic littermates were similar. IFN--
overexpressing GFAP/tTA  TRE/IFN- littermates displayed
significantly increased G ratios, indicating hypomyelination (de-
fined as a G ratio 	 0.8): 0.89  0.02 for 184/110 mice and 0.95 
0.04 for the 184/67 mice (Fig. 6C). In contrast, their triple-
transgenic (GFAP/tTA  TRE/IFN-  PLP/SOCS1) littermates
overexpressing both IFN- and SOCS1 had significantly lower G
ratios: 0.75  0.03 (within the normal range) for 184/110 
PLP/SOCS1 mice and 0.82  0.08 for 184/67  PLP/SOCS1 mice
(Figs. 6C, 8).
The myelin abnormalities were further quantified by deter-
mining the percentage of unmyelinated axons in the various
transgenic genotypes (Fig. 6D). We found no significant differ-
ence in the percentage of unmyelinated axons (9%) among the
F1 generation littermates of the MBP/IFN-  PLP/SOCS1
(172  PLP/SOCS1) double-transgenic system, regardless of ge-
notype (Fig. 6D). In the triple-transgenic GFAP/tTA  TRE/
IFN-  PLP/SOCS1 systems, however, the distribution of
Figure 6. SOCS1-mediated protection of oligodendrocytes and myelin. The IFN- expression (A), oligodendrocyte density
(CC1 cells/mm 2) (B), G ratio (C), and percentage of unmyelinated axons (D) were examined among littermates of three transgenic
systems: 172  PLP/SOCS1, 184/110  PLP/SOCS1, and 184/67  PLP/SOCS1 at postnatal day 21 (for a complete description, see
Results). The relative amount of IFN- expression differed among the systems, but no statistical difference was found in the levels
of expression between littermates from the same transgenic system overexpressing either IFN- only (IFN-) or both IFN- and
SOCS1 (IFN-  SOCS1) (A). The IFN--overexpressing littermates (IFN-) displayed significant dose-dependent oligodendro-
cyte cell loss (B) and hypomyelination (C, D) compared with the wild-type, single-transgenic control (wt/cntrl), and PLP/SOCS1
littermates (*p  0.05; n  3 animals per study group). The triple-transgenic littermates expressing both IFN- and SOCS1
(IFN-  SOCS1) displayed significant oligodendrocyte (B) and myelin preservation (C, D) compared with those overexpressing
IFN- only (IFN-) (**p  0.05; n  3 animals per study group).
Figure 7. SOCS1-mediated oligodendrocyte protection. Representative images of the quan-
titated areas from GFAP/tTA  TRE/IFN-  PLP/SOCS1 (184/67  PLP/SOCS1) mice at post-
natal day 21: A, wild type; B, PLP/SOCS1; C, 184/67; and D, 184/67  PLP/SOCS1. Immunostain-
ing with CC1/Cy3 (red) and DAPI nuclear stain (blue). Sagittal sections of corpus callosum. Scale
bar, 20 m. Note the loss of CC1 positivity in the sample from an IFN--overexpressing mouse
(C) compared with the samples from wild-type (A) and PLP/SOCS1 (B) mice, and the significant
oligodendrocyte preservation in the sample from a mouse overexpressing both IFN- and
SOCS1 (D).
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unmyelinated axons differed depending on genotype (Fig. 6D).
There was a significantly increased percentage of unmyelinated
axons in IFN--overexpressing GFAP/tTA  TRE/IFN- litter-
mates compared with wild-type and single-transgenic control
mice: 41  6% in 184/110 mice and 57  7% in 184/67 mice. In
contrast, triple-transgenic GFAP/tTA  TRE/IFN-  PLP/
SOCS1 overexpressing both IFN- and SOCS1 had a significantly
lower percentage of unmyelinated axons compared with mice
overexpressing IFN- alone: only 13  3% for 184/110  PLP/
SOCS1 mice and 17  4.5% for 184/67  PLP/SOCS1 mice (Fig.
6D). Together, these data demonstrate that oligodendroglial ex-
pression of SOCS1 protects mice from the clinical and morpho-
logical consequences of IFN- expression in the CNS during
development.
Discussion
The presence of the T-cell-derived cytokine IFN- within the
CNS is believed to play a critical role in the pathogenesis of
immune-mediated demyelinating disorders (Panitch et al., 1987;
Vartanian et al., 1995; Horwitz et al., 1997; Glabinski et al., 1999;
Tran et al., 2000; Steinman, 2001). Nevertheless, the cellular tar-
get of the effect of the cytokine remains unresolved. In this report,
we describe the generation of transgenic mice in which the oligo-
dendrocytes display a significantly reduced capacity to respond to
IFN-. These mice are protected from the injurious effect of ec-
topic expression of IFN- within the CNS, suggesting that a di-
rect deleterious effect of IFN- on oligodendrocytes contributes
to immune-mediated disease pathogenesis. As discussed below,
the work described has significant clinical implications.
Transgenic animals that ectopically express IFN- in the CNS
during postnatal development are hypomyelinated and contain
reduced numbers of oligodendrocytes (Corbin et al., 1996;
LeFerla et al., 2000; Lin et al., 2005). Moreover, the induction of
IFN- expression in the CNS after demyelinating insults results
in reduced oligodendroglial repopulation of the demyelinating
lesions and impaired remyelination (Lin et al., 2006). Previously
reported data from our laboratory suggests that the presence of
IFN- in the CNS activates an ER stress response in oligodendro-
cytes, which contributes to the observed pathological effects (Lin
et al., 2005, 2006). It is unclear, however, whether the injurious
effect of IFN- on oligodendrocytes is a result of a direct action or
whether it represents a secondary effect, possibly through micro-
glial activation.
IFN- has also been shown to have harmful effects on oligo-
dendrocytes and their progenitors in vitro. There is considerable
evidence to suggest that at least part of the injurious effect of this
cytokine is mediated through the activation of microglial cells.
IFN--treated microglia release cytotoxic agents, including nitric
oxide and tumor necrosis factor , which are known to be dam-
aging to oligodendrocytes (Merrill and Zimmerman, 1991; Mer-
rill et al., 1993, Loughlin et al., 1997). Studies using purified oli-
godendrocytes in vitro, however, suggest that the cytokine may
have a direct, harmful effect on oligodendrocytes (Torres et al.,
1995; Agresti et al., 1996; Andrews et al., 1998; Baerwald and
Popko, 1998; Lin et al., 2005). IFN- has been shown to inhibit
cell cycle exit of oligodendroglial progenitor cells, which may
predispose these cells to apoptotic death (Chew et al., 2005).
Additionally, IFN- has been shown to be a very powerful
apoptosis-inducing agent for developing oligodendrocytes
(Baerwald and Popko, 1998; Baerwald et al., 2000; Lin et al.,
2005). Oligodendrocytes that have been allowed to differentiate
in vitro to the point of expressing mature oligodendroglial mark-
ers are less sensitive to the presence of the cytokine, although they
do eventually succumb to necrosis (Baerwald and Popko, 1998).
In an effort to differentiate direct versus indirect effects of
IFN- on oligodendrocytes in vivo, we generated transgenic mice
that exhibited diminished oligodendrocyte-specific responsive-
ness to IFN-. Transgenic mice expressing either the dominant-
negative form of IFN- receptor subunit 1 (IFNGR1) or SOCS1
have been described previously (Flodstrom et al., 2001; Gonzales
at al., 2005, Hindinger et al., 2005). Overexpression of the
dominant-negative form of IFNGR1 resulted in accelerated deg-
radation of wild-type IFNGR1 and elimination of the IFN- cel-
lular binding sites (Dighe et al., 1994). SOCS1 is an intracellular
protein that blocks IFN--mediated Stat1 activation (i.e., phos-
phorylation) by Jak kinases (Starr et al., 1997; Song and Shuai
1998; Stark et al., 1998; Sakamoto et al., 2000; Yasukawa et al.,
2000; Levy and Darnell, 2002; Kubo et al., 2003). Mouse mutants
with a targeted null mutation in the SOCS1 gene exhibit abnor-
mal hypersensitivity to IFN- and die of multiorgan failure in the
presence of normal levels of the cytokine (Starr et al., 1998; Alex-
ander et al., 1999; Bullen et al., 2001). Moreover, forced expres-
sion of SOCS1 has been shown to result in a state of IFN- unre-
sponsiveness in a variety of cell types (Chong et al., 2001;
Flodstrom et al., 2001; Tunley et al., 2001, 2002; Federici et al.,
2002).
The PLP/SOCS1 mice exhibited no phenotypic or histological
abnormalities, indicating that Stat1 activation is not required for
normal oligodendrocyte development, although its involvement
in growth factor signaling has been suggested in vitro (Dell’Albani
et al., 1998). Our finding is supported by the phenotypic charac-
teristics of Stat1/ knock-out mice, which displayed no oligo-
dendrocyte or myelin abnormalities but do have significantly im-
paired IFN- cellular responses (Meraz et al., 1996). Thus, it
appears that Stat1 activation plays a differential role in oligoden-
drocyte injury and development.
Figure 8. SOCS1-mediated myelin protection. Representative images of the quantitated
areas from GFAP/tTA  TRE/IFN- PLP/SOCS1 (184/67  PLP/SOCS1) mice at postnatal day
21: A, wild type; B, PLP/SOCS1; C, 184/67; and D, 184/67  PLP/SOCS1. Electron micrographs of
corpus callosum. Scale bar, 500 nm. Note the hypomyelination in the sample from an IFN--
overexpressing mouse (C) compared with the samples from wild-type (A) and PLP/SOCS1 (B)
mice and the significant myelin preservation in the sample from a mouse overexpressing both
IFN- and SOCS1 (D).
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Functional examination of the PLP/SOCS1 mice further dem-
onstrated a diminished oligodendrocyte-specific responsiveness
to IFN-, including inhibition of Stat1 activation (i.e., phosphor-
ylation) and nuclear translocation and MHC class I molecule
upregulation. When crossed with transgenic mice overexpressing
IFN- in the CNS, PLP/SOCS1 mice were protected from the
deleterious clinical and histological effects of IFN-. IFN--
overexpressing transgenic mice that also carried the PLP/SOCS1
transgene displayed significant oligodendrocyte and myelin pres-
ervation and lower prevalence of tremor compared with IFN--
expressing mice without the PLP/SOCS1 transgene. Results of
our study thereby indicate that IFN- exerts a direct injurious
effect on developing oligodendrocytes.
Overexpression of SOCS1 provided cellular protection to oli-
godendrocytes, suggesting that inhibition of IFN- signaling re-
sults in reduced cellular effects. Wild-type oligodendrocytes, as
reported by others and also observed by us, express nearly unde-
tectable amounts of SOCS1 under normal, and even inflamma-
tory, conditions and have much lower SOCS1 expression com-
pared with the surrounding glial and inflammatory cells
(Polizzotto et al., 2000; Maier et al., 2002; Wang and Campbell,
2002). Such low constitutive expression may limit the oligoden-
drocyte capacity for effective downregulation of IFN-/Jak/Stat1
signaling, resulting in enhanced IFN- cellular effects. The res-
cuing effect of SOCS1 overexpression in oligodendrocytes that
was observed in our experimental system supports this
possibility.
Circumstantial and experimental evidence suggests that
IFN- plays a deleterious role in the immune-mediated demyeli-
nating disorder multiple sclerosis (Popko et al., 1997; Steinman,
2001). IFN- is found in demyelinated lesions, and its levels in
CSF correlate with disease severity (Vartanian et al., 1995; Cala-
bresi et al., 1998; Becher et al., 1999; Moldovan et al., 2003).
Administration of IFN- to multiple sclerosis patients exacer-
bated the disease, and neutralizing antibodies to IFN- have been
shown to delay disease progression (Panitch et al., 1987; Skurk-
ovich et al., 2001). Diminishing the local effect of IFN-, perhaps
through the targeted expression of SOCS1 by oligodendrocytes,
could prove to be therapeutically beneficial. Remyelinating oli-
godendrocytes after a demyelinating insult are more sensitive to
the presence of IFN- (Lin et al., 2006); therefore, such protec-
tion might be particularly useful for the promotion of
remyelination.
Stem cell therapy is rapidly gaining interest as a potential ther-
apeutic approach to demyelinating disorders such as multiple
sclerosis and adrenoleukodystrophy (for review, see Keirstead,
2005). The success of such an approach would appear to be lim-
ited, however, in immune-mediated demyelinating disorders,
because the harsh environment created by the inflammatory re-
sponse would remain. Perhaps stem cells engineered to be resis-
tant to the harmful cytokines present in the extracellular milieu of
the breached CNS would stand a better chance of surviving and
accomplishing remyelination. It is, therefore, of therapeutic in-
terest to identify signaling pathways that play differential roles in
oligodendrocyte injury and development. Our results describing
inhibition of IFN--mediated oligodendrocyte injury without
induction of any observable oligodendrocyte or myelin abnor-
malities provide support for such an approach.
In summary, we have demonstrated that the forced expression
of SOCS1 in oligodendrocytes of transgenic mice protects against
the deleterious effects of IFN- on oligodendrocytes and the pro-
cess of myelination. Our results strongly indicate that the delete-
rious effect of IFN- on myelinating oligodendrocytes is attrib-
utable, at least in part, to a direct adverse effect on these cells.
Moreover, our work suggests that forced expression of SOCS1 in
oligodendrocytes might provide protection against the harsh en-
vironment in immune-mediated demyelinating disorders.
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